|
IQVIA™ Real-World Insights Bibliography
| Long-term cost-effectiveness of zoledronic acid versus risedronate in patients with Paget's disease of the bone in Germany |
| Author(s): Kurth AA1 , Kotowa W2, Goel D3, Maiwenn JA4 |
| Affiliations(s): 1 Orthopaedische Universitaetsklinik Stiftung Friedrichsheim, Frankfurt am Main, Germany 2 IMS Health, Nuremberg, Germany 3 Novartis Pharma GmbH, Nuremberg, Germany 4 Institute for Medical Technology Assessment, Erasmus Medical Center, Rotterdam, Netherlands |
Publication(s): ECCEO 6, 2006, March 15-18, Vienna, Austria
|
| Document Type(s): Oral presentation, |
| Countries: Germany, |
C:
Y: |
Obesity,
2006 |
|
L:
A: |
English
Cost effectiveness, |
|
 |
| |
| |
| Zoledronic acid in the long-term management of Paget's disease of the bone in Germany - a cost savings approach? |
| Author(s): Kurth AA1, Kotowa W2, Fricke F-U2, Quednau K3, Maiwenn JA4 |
| Affiliations(s): 1 Orthopaedische Universitaetsklinik Stiftung Friedrichsheim, Frankfurt am Main, Germany 2 IMS Health, Nuremberg, Germany 3 Novartis Pharma GmbH, Nuremberg, Germany 4 Institute for Medical Technology Assessment, Erasmus Medical Center, Rotterdam, Netherlands |
Publication(s): ISPOR 9th Annual International Congress, 29-31 October 2006, Copenhagen, Denmark
|
| Document Type(s): Oral presentation, |
| Countries: Germany, |
C:
Y: |
Obesity,
2006 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Zoledronic acid in the long-term management of Paget's disease of the bone in Germany - a cost savings approach? |
| Author(s): Kurth AA1, Kotowa W2, Fricke F-U2, Quednau K3, Maiwenn JA4 |
| Affiliations(s): 1 Orthopaedische Universitaetsklinik Stiftung Friedrichsheim, Frankfurt am Main, Germany 2 IMS Health, Nuremberg, Germany 3 Novartis Pharma GmbH, Nuremberg, Germany 4 Institute for Medical Technology Assessment, Erasmus Medical Center, Rotterdam, Netherlands |
Publication(s): Value in Health 2006, 9(6)
|
| Document Type(s): Abstract, |
| Countries: Germany, |
C:
Y: |
Obesity,
2006 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Long-term cost-effectiveness of zoledronic acid versus risedronate in patients with Paget's disease of the bone in Germany |
| Author(s): Kurth AA1 , Kotowa W2, Goel D3, Maiwenn JA4 |
| Affiliations(s): 1 Orthopaedische Universitaetsklinik Stiftung Friedrichsheim, Frankfurt am Main, Germany 2 IMS Health, Nuremberg, Germany 3 Novartis Pharma GmbH, Nuremberg, Germany 4 Institute for Medical Technology Assessment, Erasmus Medical Center, Rotterdam, Netherlands |
Publication(s): ECCEO 6, 2006, March 15-18, Vienna, Austria
|
| Document Type(s): Abstract, |
| Countries: Germany, |
C:
Y: |
Obesity,
2006 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
 4 of 4
|
|
